Icon
+91 94997 68112
Login Register

RYTELO - (47MG)

IMETELSTAT SODIUM None
47MG
Less Than $1000 mn
None None
None None
None None
RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Yes
RYTELO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

RYTELO - (188MG)

IMETELSTAT SODIUM None
188MG
Less Than $1000 mn
None None
None None
None None
RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Yes
RYTELO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.